Valvular & structural heart disease

Impact of Severity and Extent of Iliofemoral Atherosclerosis on Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement (TAVR)

JACC Cardiovasc IntervPublished Prospective registry study

Authors' conclusion

The Hostile score proved useful in predicting non-puncture site vascular complications after TAVR.

Study context

Population
Patients undergoing transfemoral TAVR with contemporary devices, March 2014–June 2022 (SwissTAVI Registry)
Participants
2,023 patients
Exposure
Hostile score for prediction of vascular complications after transfemoral TAVR
Outcome
Puncture and non-puncture site iliofemoral vascular complications (validity of Hostile score)
Methodological detailsvalidation of a risk score
  • Validation of a risk score

Main finding

As reported in the abstract

Hostile score prediction of vascular complications

Vascular complications

1.00

median · IQR 0–5.00

No complications

1.00

median · IQR 0–4.00

P < 0.001

Puncture site vascular complications
106 (5.2%)
Non-puncture site vascular complications
28 (1.4%)
AUC, puncture site vascular complications
0.554
AUC, non-puncture site vascular complications
0.829
Higher Hostile score, independent predictor of non-puncture site complications
OR 1.91 (1.55-2.35) (95% CI)

Observational data: associations, not effects.

Further findings

Independent predictors of puncture site vascular complications

Higher BMI
OR 1.23 (1.04-1.50) (95% CI)
Prostar vs ProGlide
OR 6.03 (2.23-16.30) (95% CI)
MANTA vs ProGlide
OR 6.18 (2.67-14.27) (95% CI)

Other independent predictor of non-puncture site vascular complications

Female sex
OR 2.69 (1.12-6.42) (95% CI)

Original publication

Impact of Severity and Extent of Iliofemoral Atherosclerosis on Clinical Outcomes in Patients Undergoing TAVR. JACC Cardiovasc Interv. Published 9 October 2024. doi:10.1016/j.jcin.2024.07.009

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.